Suzhou Genhouse Bio Co., Ltd.

勤浩医药（苏州）股份有限公司

Develops innovative oncology drugs targeting RAS signalling pathways and synthetic lethality, including a SHP2 inhibitor for solid tumours and KRAS-mutated cancers; pre-revenue clinical-stage biotech based in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Key long-term agreements
• Losses and path to profitability
• Net current liabilities or net liabilities
• Cash burn and runway
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech